Navigation Links
Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
Date:5/21/2009

HUNTINGTON BEACH, California and AMSTERDAM, May 21 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple studies at the American Society of Clinical Oncology Annual Meeting, May 29 - June 2, 2009, in Orlando, Florida.

The study results further underpin the broad predictive and prognostic power of Agendia's breast cancer recurrence test MammaPrint(R) and highlight promising data on Agendia's new colon cancer recurrence test, ColoPrint(TM). Visitors can meet the Agendia team in booth #2014 and study results will be discussed at the following sessions:

    Date: Saturday, May 30, 2009
    ORAL PRESENTATION
    Abstract #512
    Time: 5:00PM - 5:15PM
    Location: Level 2, West Hall D1
    The 70-gene profile and chemotherapy benefit in 1,600 breast cancer
    patients
    R. A. Bender, M. Knauer, E. J. Rutgers, A. M. Glas, F. A. de Snoo, S. C.
    Linn, L. J. Van 't Veer

    Date: Saturday, May 30, 2009
    ORAL PRESENTATION
    Abstract # LBA515
    Time: 3:00PM - 6:00PM
    Location: Level 2, West Hall D1
    Breast cancer molecular profiles predict tumor response of neoadjuvant
    Doxorubicin and Taxol, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
    L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van 't
    Veer, J. Gray, E. Petricoin, K. Conway, D. Berry, I-Spy Investigators

    Date: Saturday, May 30, 2009
    POSTER PRESENTATION
    Abstract #6570
    Time: 2:00PM - 6:00PM
    Location: Level 2, West Hall C
    Cost effectiveness of targeting chemotherapy with the 70-gene
    prognostic signature in early stage breast cancer (ESBC) patients
    K. B. Tong, E. Chen, G. Brink, R. Bender, F. de Snoo, J. Malin

    Date: Sunday, May 31, 2009
    POSTER DISCUSSION
    Abstract #535
    Time: 8:00AM - 12:00PM
    Location: Level 2, West Hall D1, W240A
    Outcome prediction by the 70-gene profile in the context of the National
    Comprehensive Cancer Network (NCCN) guideline
    F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers,
    A. M. Glas, S. C. Linn, L. J. Van 't Veer

    Date: Sunday, May 31, 2009
    POSTER PRESENTATION
    Abstract #4036
    Time: 8:00 AM - 12:00 PM
    Location: Level 2, West Hall C
    Development and validation of a robust prognostic and predictive
    signature for colorectal cancer (CRC) patients
    A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga,
    P. J. Kuppen, I. Simon, L. J. Van 't Veer, R. Tollenaar

    Date: Sunday, May 31, 2009
    POSTER DISCUSSION
    Abstract #518
    Time: 8:00AM - 12:00PM
    Location: Level 2, West Hall D1, W240A
    Early determination of metastatic potential in breast cancer: the 70-gene
    signature in small tumors
    M. Knauer, S. Mook, V. Retel, M. Kok, J. Wesseling, A. M. Glas, E. J.
    Rutgers, L. J. van 't Veer, S. C. Linn

    Date: Monday, June 01, 2009
    POSTER PRESENTATION
    Abstract #11083
    Time: 1:00PM - 5:00PM
    Location: Level 2, West Hall C
    Combining multi-gene profiling of molecular subtypes with the 70-gene
    profile for classification of breast cancer
    L. Stork-Sloots, O. Krijgsman, P. Roepman, F. A. de Snoo, R. A. Bender,
    A. M. Glas

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. The Company was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
2. Agendia Joins the Personalized Medicine Coalition (PMC)
3. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
4. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
5. Agendia BV Appoints Clinical and Scientific Advisory Board
6. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
9. Agendia Appoints New Chief Financial Officer
10. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
11. Agendia Appoints VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 NanoStruck Technologies Inc. ... ( Frankfurt : 8NSK) gibt bekannt, ... 13. August 2015 die Genehmigung von der CNSX ... 200.000.000 Einheiten auf 400.000.000 Einheiten zu erhöhen, um ... wurden 157.900.000 Einheiten mit dem ersten Teil der ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... is pleased to announce the appointment of John Tilton as Chief Commercial Officer.  ... Director and one of the founding commercial leaders responsible for the commercialization of ...
(Date:4/27/2016)... ... 27, 2016 , ... PathSensors, Inc., a leading environmental testing ... will assist PathSensors in expanding the use of the company’s CANARY® technology in ... platform for the detection of harmful pathogens, including a number of bacteria, viruses, ...
(Date:4/27/2016)... ... 2016 , ... Global Stem Cells Group CEO Benito Novas announced ... of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received his Ph.D. ... for hematologic disorders and the suppression of graft vs. host disease (GVHD) under UM ...
Breaking Biology Technology:
(Date:3/10/2016)... BLUE BELL, Pa. , March 10, 2016   ... U.S. Customs and Border Protection (CBP) is testing ... in San Diego to help identify ... United States . The test, designed to help determine ... outdoor, pedestrian environment, began in February and will run until ...
(Date:3/8/2016)... March 8, 2016   Valencell , the ... announced it has secured $11M in Series D ... a new venture fund being launched by UAE-based ... from existing investors TDF Ventures and WSJ Joshua ... continue its triple-digit growth and accelerate its pioneering ...
(Date:3/2/2016)... 2016 http://www.researchandmarkets.com/research/wzwqtz/global_biometrics ... the  "Global Biometrics Market in Hospitality Sector ... http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics market in ... CAGR of around 27%   --> ... the addition of the  "Global Biometrics Market ...
Breaking Biology News(10 mins):